Amlexanox vs Liraglutide
Research Verdict
Liraglutide is the stronger research reference for the stated comparison criteria. Liraglutide: FDA approved (Saxenda) for obesity, SCALE trial (Pi-Sunyer et al.
Quick Answers
Which is better, Amlexanox or Liraglutide?
Liraglutide is the stronger research reference for the stated comparison criteria. Liraglutide: FDA approved (Saxenda) for obesity, SCALE trial (Pi-Sunyer et al.
What is the key difference between Amlexanox and Liraglutide?
Liraglutide is a GLP-1 receptor agonist with well-characterized satiety and metabolic effects; amlexanox inhibits IKKe/TBK1 targeting inflammatory metabolic signaling - established drug class vs. exploratory mechanism.
Evidence Comparison
Liraglutide: FDA approved (Saxenda) for obesity, SCALE trial (Pi-Sunyer et al. NEJM 2015, n=3,731) showing 8.0% weight loss vs. 2.6% placebo. Amlexanox: single pilot study (Reilly et al. 2015, Cell Metab, n=42) with modest metabolic improvements. Liraglutide is categorically stronger on every evidence dimension.
Evidence Context Favoring Amlexanox
Research into IKKe/TBK1 inflammatory metabolic pathways specifically, accepting pilot-stage evidence.
Evidence Context Favoring Liraglutide
Any metabolic or weight management application requiring robust evidence - liraglutide has Phase 3 RCT data and FDA approval.
Side-by-Side Snapshot
| Evidence grade | Amlexanox: Level C Liraglutide: Level A |
|---|---|
| Research status | Amlexanox: Phase 2 Liraglutide: FDA Approved |
| Primary category | Amlexanox: Weight Loss & Metabolic Liraglutide: Weight Loss & Metabolic |
| Cited studies | Amlexanox: 2 Liraglutide: 2 |